Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1728545 | 0.90 | NR4A2 (0.47) | NR4A2CYP2C9EGLN1ENPP2 | |
| SCHEMBL3775596 | 0.87 | NR4A2 (0.66) | NR4A2CYP2C9EGLN1 | |
| SCHEMBL3770038 | 0.86 | KDM4E (0.49) | NR4A2CYP2C9EGLN1 | |
| SCHEMBL1733053 | 0.83 | ENPP2 (0.39) | NR4A2CYP2C9EGLN1ENPP2 | |
| SCHEMBL1733982 | 0.81 | NR4A2 (0.48) | NR4A2CYP2C9EGLN1 | |
| SCHEMBL23535810 | 0.80 | ENPP2 (0.51) | ENPP2 | |
| SCHEMBL15419054 | 0.78 | SIRT2 (0.37) | NR4A2CYP2C9ENPP2 | |
| SCHEMBL14496825 | 0.77 | ENPP2 (0.47) | ENPP2 | |
| SCHEMBL1733130 | 0.76 | NR4A2 (0.73) | NR4A2CYP2C9PTGS1PTGS2EGLN1 | |
| SCHEMBL3660590 | 0.75 | EGLN1 (0.66) | NR4A2CYP2C9PTGS1PTGS2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691990-B2 | 6-heterocyclic imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-04-08 | — | — | US | claimed |
| EP-2225240-B1 | Derivatives of 6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2014-01-22 | — | — | EP | claimed |
| US-20130041152-A1 | 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | PEYRONEL JEAN-FRANCOIS (FR) | 2013-02-14 | — | — | US | claimed |
| EP-2225243-B1 | Derivatives of N-heterocyclic-6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2011-11-16 | — | — | EP | claimed |
| US-20100317675-A1 | 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| US-20100317686-A1 | N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| US-8691990-B2 | 6-heterocyclic imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-04-08 | — | — | US | disclosed |
| EP-2225240-B1 | Derivatives of 6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2014-01-22 | — | — | EP | disclosed |
| US-20130041152-A1 | 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | PEYRONEL JEAN-FRANCOIS (FR) | 2013-02-14 | — | — | US | disclosed |
| US-8314109-B2 | 6-heterocyclic-imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| EP-2225243-B1 | Derivatives of N-heterocyclic-6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2011-11-16 | — | — | EP | disclosed |
| US-20100317686-A1 | N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| US-20100317675-A1 | 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| EP-2225244-A1 | IMIDAZOÝ1,2-A¨PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | Sanofi-Aventis (FR) | 2010-09-08 | — | — | EP | disclosed |
| EP-2225243-A2 | DERIVATIVES OF N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZOÝL,2- A¨PYRIDINE-2-CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009112651-A1 | IMIDAZO[1,2-A]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009106751-A2 | DERIVATIVES OF N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[L,2- A]PYRIDINE-2-CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041152-A1 | 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | XDH, REN, IDH2 | NR4A2 2105/4885CYP2C9 209/4885PTGS1 1703/4885 |
| US-20100317675-A1 | 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | REN, IDH2, GLS | NR4A2 1987/4885CYP2C9 231/4885PTGS1 1247/4885 |
| US-20100317686-A1 | N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | IDH1, IDH2, XDH | NR4A2 1619/4885CYP2C9 323/4885PTGS1 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.